
On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.
- TERN stock is struggling to find support. Check the fundamentals here

On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.